abbvie glp-1 receptor agonist weight management diabetes treatments What's New in Obesity Treatment? Upcoming wave of hormone-based therapies

Ovarian angiogenesis in polycystic ovary syndrome

Notably, sensitivity analysis by omitting one of the studies [22] for the subgroup with treatment durations of 6 months indicated a significantly greater WL in the GLP-1RAs group compared to placebo (SMD = 0.79

Consequently, clinicians can prescribe these treatments with greater confidence

These results suggest that GLP-1RAs may be preferred to sulfonylureas as an add-on therapy [65]

Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca plc, Sanofi S.A., Merck & Co., Inc., Boehringer Ingelheim International GmbH, and Zealand Pharma A/S are global key players in the market

doi: 10.1037/ccp0000552